Last reviewed · How we verify
TGF-β2 antisense oligonucleotide
At a glance
| Generic name | TGF-β2 antisense oligonucleotide |
|---|---|
| Also known as | ISTH0036 |
| Sponsor | Isarna Therapeutics GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer (PHASE2, PHASE3)
- TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor (PHASE1)
- Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TGF-β2 antisense oligonucleotide CI brief — competitive landscape report
- TGF-β2 antisense oligonucleotide updates RSS · CI watch RSS
- Isarna Therapeutics GmbH portfolio CI